Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

The current study is a prospective randomized controlled clinical study that will be conducted on about 100 cancer patients.

Study duration The study will be conducted from January 2025 to September 2025

Study population Group I (control): includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy.

Group II (Test group) includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy plus 450 mg diosmin and 50 mg hesperidin combination orally twice daily.

Inclusion Criteria:

• Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

Exclusion Criteria:

• -History of allergic reactions attributed to drugs in the study.
• Pregnant women.
• Life expectancy less than 6 months
• Inability or unwillingness to comply with research protocols.
• Cancer patients with impaired renal function (creatinine clearance < 50 mL/min)
• Preexisting hearing loss.
• Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.